Evaxion Biotech A/S (EVAX) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free EVAX Stock Alerts $3.76 +0.04 (+1.08%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Receives Nasdaq NotificationMay 10, 2024 | globenewswire.comEvaxion Receives Nasdaq NotificationMay 7, 2024 | americanbankingnews.comEvaxion Biotech A/S (NASDAQ:EVAX) Shares Down 1% April 17, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Decreased by 13.62% to 11.99April 17, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | finance.yahoo.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 17, 2024 | globenewswire.comEvaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01April 3, 2024 | finance.yahoo.comQ4 2023 Evaxion Biotech A/S Earnings Call (Danish)April 3, 2024 | finance.yahoo.comEvaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call TranscriptApril 2, 2024 | marketwatch.comADRs End Lower; Meta Data Slides 22%April 2, 2024 | globenewswire.comEvaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus InfectionMarch 28, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 27, 2024 | investorplace.comEVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023March 27, 2024 | globenewswire.comEvaxion Announces Business Update and Full Year 2023 Financial ResultsMarch 22, 2024 | finance.yahoo.comWhen Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Evaxion Biotech Amid AI-Driven Vaccine Development MilestonesMarch 19, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology PlatformMarch 19, 2024 | globenewswire.comEvaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ PlatformMarch 13, 2024 | msn.comNeuroBo Phase 2a study for MASH drug to proceed as plannedFebruary 29, 2024 | globenewswire.comEvaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology InnovationsFebruary 24, 2024 | msn.comEvaxion Biotech A (EVAX) Price Target Increased by 414.29% to 18.36February 20, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | finance.yahoo.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 20, 2024 | globenewswire.comEvaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSDFebruary 12, 2024 | markets.businessinsider.comBuy Rating for Evaxion Biotech: AI Revolutionizing Immunotherapy and Vaccine DevelopmentFebruary 7, 2024 | investing.comEvaxion Biotech AS (EVAX)February 7, 2024 | finance.yahoo.comEvaxion Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 6, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Closing of $15 Million Public OfferingFebruary 6, 2024 | finance.yahoo.comEvaxion Announces Closing of $15 Million Public OfferingFebruary 1, 2024 | msn.comEvaxion Biotech to raise ~$15M through public offering of shares and warrantsFebruary 1, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:02 AM with a stated reason of "LULD pause."February 1, 2024 | finance.yahoo.comEvaxion Biotech Announces Pricing of $15 Million Public OfferingFebruary 1, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:02 AM with a stated reason of "LULD pause."January 29, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 25, 2024 | msn.comEvaxion Biotech to develop new vaccines for cancerJanuary 24, 2024 | morningstar.comADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%January 24, 2024 | msn.comEvaxion stock rallies 120% on AI-based cancer vaccine programJanuary 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 10:01 AM with a stated reason of "LULD pause."January 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 10:01 AM with a stated reason of "LULD pause."January 24, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 24, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsJanuary 24, 2024 | marketwatch.comEvaxion ADSs Rise 17% After ADS Ratio ChangeJanuary 24, 2024 | finance.yahoo.comEvaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered TargetsJanuary 23, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 09:01 AM with a stated reason of "LULD pause."January 22, 2024 | finanznachrichten.deEvaxion Biotech: Evaxion Announces Completion of ADS Ratio ChangeJanuary 22, 2024 | morningstar.comADRs End Lower; Evaxion Biotech A/S Drops 45%January 22, 2024 | finance.yahoo.comEvaxion Announces Completion of ADS Ratio ChangeJanuary 22, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 11:01 AM with a stated reason of "LULD pause."January 22, 2024 | marketbeat.comTrading was temporarily halted for "EVAX" at 07:01 PM with a stated reason of "News pending."January 8, 2024 | finance.yahoo.comEvaxion Announces Plan to Implement ADS Ratio Change Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+. Click here to see why this small company is trusted by the Mayo Clinic EVAX Media Mentions By Week EVAX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼0.220.54▲Average Medical News Sentiment EVAX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼42▲EVAX Articles Average Week Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aptose Biosciences News Today AIM ImmunoTech News Today ZIVO Bioscience News Today Senti Biosciences News Today NKGen Biotech News Today Tevogen Bio News Today Coeptis Therapeutics News Today Genetic Technologies News Today BioCardia News Today Organovo News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVAX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
